In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro) as maintenance therapy after bortezomib (Velcade)-based induction therapy in real-world patients with multiple myeloma (MM). The data showed that the outcomes of these patients in the real-world setting were good with manageable side effects. Some background...
Read MoreType(s) of biological/targeted therapy-Bortezomib Posts on Medivizor
Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment
In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment. This study concluded that this treatment combination was effective in...
Read MoreLong-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma
In a nutshell The study evaluated long-term outcomes of RVD involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) and risk-based maintenance therapy in patients with newly diagnosed multiple myeloma (MM). The authors found this approach to be beneficial for survival in a large group of patients. Some background RVD...
Read MoreMinimal residual disease and its association with transplant success in Multiple Myeloma.
In a nutshell This study monitored the development of minimal residual disease (MRD) after transplant for multiple myeloma (MM). The main finding was that different patterns of MRD development are associated with varying success after stem cell transplant for MM. Some background There are many treatments for MM. Patients are often cured fully by...
Read MoreThe effects of Len/Dex combination therapy in relapsed multiple myeloma.
In a nutshell This study investigated the effects of lenalidomide/dexamethasone (Revlimid/Dexasone) combination treatment in relapsed multiple myeloma. The main finding was that the type of relapse may predict how a patient responds to lenalidomide/dexamethasone treatment. Some background Common treatments for multiple myeloma (MM) include...
Read More